EBOVAC-Salone Extension

CompletedOBSERVATIONAL
Enrollment

653

Participants

Timeline

Start Date

July 22, 2019

Primary Completion Date

June 28, 2022

Study Completion Date

July 14, 2022

Conditions
Ebola Virus Disease
Interventions
OTHER

Follow-up

No investigational vaccine will be administered during this study

OTHER

Blood sample collection

Blood sampling to assess vaccine-induced immune responses will be conducted only in cohort 1 in a subsample consisting of approximately 102 adults and 165 children (55 from each of the three paediatric age groups that were enrolled in EBOVAC-Salone: 12-17 year olds, 4-11 year olds, and 1-3 year olds).

Trial Locations (2)

Unknown

EBOVAC Rokupr clinic, Rokupr

EBOVAC Kambia 1 clinic, Kambia

All Listed Sponsors
collaborator

University of Sierra Leone

OTHER

collaborator

Janssen Vaccines & Prevention B.V.

INDUSTRY

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

Universiteit Antwerpen

OTHER

lead

London School of Hygiene and Tropical Medicine

OTHER

NCT03820739 - EBOVAC-Salone Extension | Biotech Hunter | Biotech Hunter